News Center

Featured

ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Add...

ACELYRIN, INC., a late- stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the closing of its previously announced upsized initial public offering

Read More Arrow purple
Izokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Izokibep for the treatment of moderate-to-severe plaque psoriasis - a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer 
ACELYRIN, INC. Reports First Quarter 2023 Financial Results And Recent Highlights
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering